MyTEPI Collaborates With Leading Scientists To Advance Consumer-Centric Cannabis Technology

Tech company MyTEPI has announced its intention to partner with world-renowned scientists Dr. John Abrams and Dr. Jean Talleyrand. This collaboration is poised to develop cutting-edge, science-based applications specifically designed with the cannabis consumer in mind.

Dr. Abrams and Dr. Talleyrand, both prominent figures in cannabis research, are co-founders of the Clinical Endocannabinoid System Consortium (CESC). The CESC has been an instrumental entity in cannabis research, boasting a collective experience of over six decades in drug development and clinical cannabis observation.

Dr. Abrams has established a prolific career in the cannabis industry. His notable achievements include the development of an innovative algorithm for cannabis chemotype categorization, which followed his success in antibody therapeutic research.

Dr. Talleyrand, recognized globally as one of the most experienced clinician in the cannabis field, founded MediCann in 2004. As a cannabis physician referral service, MediCann has facilitated over half a million patient consultations. Dr. Talleyrand has also led the Dosing Project, a unique clinical program using observational methodologies to decipher cannabis dose effect relationships.

This collaboration will also witness the scientists contributing to MyTEPI’s advisory board as senior advisors, thereby strengthening the company’s commitment to enhancing consumer health and wellness.

Livi McKay, the founder and CEO of MyTEPI, welcomed the partnership enthusiastically, saying, "We are thrilled to be working with Dr. Abrams and Dr. Talleyrand in our combined vision to bring an evidence-based, consumer-centric approach to guiding people to the products they need."

Emphasizing the consumer-centric focus, Dr. Abrams said, "We have developed a robust cannabis classification system, anchored by chemistry, which is easily communicated to consumers. They now can correlate their individual experiences with product type. Our alignment with MyTEPI advances our goal of fostering widespread adoption of our categorization platform across the Cannabis Industry."

Dr. Talleyrand also voiced his approval of the collaboration, pointing out the potential for progress in the field: "This partnership addresses an unmet need within the Cannabis-using community. It also facilitates our research goals aimed at understanding how Dosage and Demography influence the Cannabis Mind."

This breakthrough partnership between MyTEPI and the esteemed scientists promises to usher in a new era of consumer-oriented innovation in the cannabis industry. Stay tuned for more.